Steatosis and Diastolic Dysfunction

Lindsey, Jason B.; Marso, Steven P.

doi:10.1016/j.jacc.2008.08.038

Cited by 11 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the high fat percentage measured in the cardiovascular disease group (G2, Table 2), there was also exceptionally heterogeneous fat distribution. Impaired cardiac function, both systolic and diastolic (8, 11, 12, 17, 18), has been shown to be correlated with increased intramyocellular lipid accumulation. It can be postulated that cardiovascular disease might lead to weakening of the muscle, resulting in fibro‐fatty hearts.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneous distribution of myocardial steatosis—An ex vivo evaluation

Liu

Ambale-Venkatesh

et al. 2012

Magnetic Resonance in Med

View full text Add to dashboard Cite

Myocardial fat accumulation could occur in diseased hearts. The degree of heterogeneity is unknown because accurate assessment is difficult using conventional 1H-MRS techniques in a beating heart. The purpose of this study was to characterize the distribution of intramyocellular lipid content and to determine its association with disease characteristics. 1H-MRS was performed on formalin-fixed slices of human hearts at various circumferential locations (N=55). 29% of the hearts had the highest fat content measured in the septum, followed by posterior (27%), lateral (26%), and anterior (18%) wall. Age was significantly correlated with the mean fat percentages (r2=0.12, p=0.007). Those who died from cardiovascular disease demonstrated significantly higher and more heterogeneous fat distribution than those who did not (1.62±1.1% vs 0.59±0.4%, p=0.002). In summary, septal fat content is representative of mean fat percentage. Fat content increases with age; fat distribution may be heterogeneous when associated with cardiovascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Heterogeneous distribution of myocardial steatosis—An ex vivo evaluation

Liu

Ambale-Venkatesh

et al. 2012

Magnetic Resonance in Med

View full text Add to dashboard Cite

show abstract

“…Adult animals are capable of tolerating a higher concentration of erucic acid compared with young animals . Heart failure (diastolic dysfunction) has been also shown in humans . The therapeutic application of Lorenzo's oil (consisting of erucic acid) in adrenoleukodystrophy (ALD) patients results in haematological effect, especially thrombocytopenia and morphological alterations of thrombocytes, at erucic acid concentration of about 0.1 g kg −1 bw per day…”

Section: Reduction In Antinutritive Compoundsmentioning

confidence: 99%

Current Research Developments on the Processing and Improvement of the Nutritional Quality of Rapeseed (Brassica napus L.)

Beszterda

Nogala‐Kałucka

2019

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

Brassica napus is cultivated largely as a winter or semi‐winter form in Europe and Asia, respectively, whereas spring‐sown rape types are more adapted to the climatic conditions in Canada, northern Europe, and Australia. This plant, the third most important oil crop in the world after maize and oil palm, has had a unique history among those crops that have been targets of breeding and genetic modification. Although agronomy and genetic manipulations of B. napus plants to create seed with substantially no erucic acid content in the seed oil and meal largely free from aliphatic glucosinolates were major breakthroughs, opportunities for further advances in the reduction of antinutritive compounds/enhancement of bioactive compounds, in oil and meal health safety and quality, as well as in agronomic performance and pest resistance, are still greater today than they have ever been. Understanding and application of genetic control for key agronomic traits in B. napus, such as seed oil composition and concentration as well as their environmental interactions, are the main targets, which will underpin the development of the crop for cultivation in an extensive range of environments. It is also needed to improve phytochemical content through traditional breeding programs or through bioengineering of the phenylpropanoid pathway, leading to desirable secondary metabolite accumulation. This paper is a review of modifications (in the field of biotechnology, agronomy, and processing) that have been applied to improve the nutritional value of B. napus L. Practical Applications: This paper has value for people starting their scientific work in the field related to the B. napus biotechnology and nutritional value of vegetable oils. In addition, it is a current compedium of knowledge for people working professionally in the oil industry. Moreover, this article is a cross‐section of the current achievements of genetic engineering in improving the composition of rapeseed and indicates key publications on this subject. Brassica napus L., the third most important oil crop in the world after maize and oil palm, has a unique history among those crops that are targets of breeding and genetic modification. Effective tools of processing, biotechnology, and agronomy are essential to produce rapeseed oil with a high amount of bioactive compounds and continue to be employed in strengthening the product versatility.

show abstract

“…47 While there is clearly an association between myocardial TG and diastolic dysfunction in T2DM patients, no conclusions can be made regarding causality. 48 Glucotoxicity also has a deleterious effect on the heart. We have shown that glucose uptake increases more than glucose oxidation when a mammalian heart is placed under metabolic stress; the stress is then eliminated with treatment of rapamycin (an mTOR inhibitor) or metformin (via adenosine monophosphate-activated protein kinase activation).…”

Section: Lipotoxicity and Glucotoxicity In The Heartmentioning

confidence: 99%

The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

Riggs

Ali

Taegtmeyer

et al. 2015

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

The concurrent management of type 2 diabetes mellitus (T2DM) and chronic congestive heart failure presents several therapeutic challenges. Of concern is that insulin and insulin-sensitizing medications detrimentally "flood" the heart with energy-providing substrates, including fats and glucose. In this population, treatment of T2DM should focus on the reduction of increased substrate supply. Sodium glucose cotransporter-2 (SGLT-2) inhibitors, a new class of antidiabetic medication, operate via this principle by blocking the reabsorption of glucose in the kidney and subsequently releasing glucose through the urine. In this review, we begin with an examination of the mechanisms of glucotoxicity and lipotoxicity in the heart. Then we analyze the potential role of SGLT-2 inhibitor therapy in patients with concurrent T2DM and chronic heart failure. Based on the available evidence, SGLT-2 inhibitors are safe and can be recommended to treat T2DM in patients with chronic heart failure and intact renal function. Further studies are in progress to assess long-term survival benefits.

show abstract

Steatosis and Diastolic Dysfunction

Cited by 11 publications

References 16 publications

Heterogeneous distribution of myocardial steatosis—An ex vivo evaluation

Heterogeneous distribution of myocardial steatosis—An ex vivo evaluation

Current Research Developments on the Processing and Improvement of the Nutritional Quality of Rapeseed (Brassica napus L.)

The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

Contact Info

Product

Resources

About